{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["84(6)"],"submitter":["Lee TA"],"pubmed_abstract":["Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1-mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1."],"journal":["Cancer research"],"pagination":["800-807"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10940856"],"repository":["biostudies-literature"],"pubmed_title":["Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy."],"pmcid":["PMC10940856"],"pubmed_authors":["Liu SH","Chao CH","Tsai EY","Hsu Hung SD","Chang SJ","Li CW","Lai YJ","Yamaguchi H","Lee TA"],"additional_accession":[]},"is_claimable":false,"name":"Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.","description":"Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1-mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-05T12:06:18.293Z","creation":"2025-04-05T12:06:18.293Z"},"accession":"S-EPMC10940856","cross_references":{"pubmed":["38231470"],"doi":["10.1158/0008-5472.CAN-23-2664"]}}